Search Results
Your search for ,waY matches 3938 pages
Showing 51 - 100As a Cancer Survivor, My Main Worry Now Is Affording Health Insurance
Until 3 years ago, cancer was so utterly frightening to me that I avoided discussing the disease or even mentioning the word as much as possible. I sympathized with a friend when she was diagnosed with lung cancer, but I never expected to be in her position. I’m a never-smoker, and except for a...
AI Simplifies Patients' Comprehension of CT Reports—but Errors Are Possible
Simplified oncologic computed tomography (CT) reports using large language models (LLMs) enabled patients to better understand the results of their restaging CT scans and reduced overall reading burden, according to the results of a study published in Radiology. However, the study also revealed...
Significant Medicare Physician Reimbursement Methodology Changes Finalized for 2026
The Centers for Medicare & Medicaid Services (CMS) released the Medicare Physician Fee Schedule final rule for 2026 on October 31, 2025.1 The rule finalizes physician reimbursement and policy reforms under the Physician Fee Schedule as well as changes to reporting requirements and policy...
Proton vs Photon Radiation Therapy for Nonmetastatic Breast Cancer: Focus on Patient Perspective and Satisfaction
Health-related quality-of-life analyses for proton radiation therapy and photon radiation therapy in patients with nonmetastatic breast cancer showed similar impacts on quality of life with both treatments, according to findings from the phase III RadComp consortium trial. Shannon M. MacDonald, MD, ...
The Consequences of Climate Change on Cancer Development and Patient Care
In 2021, The ASCO Post had a wide-ranging discussion with Robert A. Hiatt, MD, PhD, Professor in the Department of Epidemiology and Biostatistics at the University of California, San Francisco (UCSF), and Associate Director of Population Sciences at UCSF Helen Diller Family Comprehensive Cancer...
Reducing the Impact of Climate-Induced Events on Patients and Oncology Staff
Although 2023 made headlines as the hottest year in human history,1 drawing the world closer to breaching the goals outlined in the Paris Agreement to substantially reduce global greenhouse gas emissions to limit global warming to well below 2°C above preindustrial levels (and preferably to...
Intensity-Modulated Radiation Therapy vs Proton Therapy for Oropharyngeal Cancer
The phase III TORPEdO trial reported no meaningful differences between intensity-modulated radiation therapy (IMRT) and proton beam therapy at 1 year in terms of patient-reported quality of life, swallowing function, or feeding tube dependence for individuals with locally advanced oropharyngeal...
NCCN Guidelines to Be Integrated Into OpenEvidence's Medical AI Platform
The National Comprehensive Cancer Network (NCCN) has entered into a licensing agreement with OpenEvidence that would make the NCCN Clinical Practice Guidelines in Oncology accessible through OpenEvidence's AI–powered medical platform. “This collaboration will help clinicians access trusted...
My 50 Years in Lymphoma: Lessons Learned?
In the 50 years now since my fellowship training, there have been major advances in the diagnosis, staging, prognostic scoring, treatment, and response assessment of lymphomas. To conjure up the future, we must first appreciate the present by understanding how it arose from the past.1 So, a trip in ...
Defying the Odds
In early 2023, I began experiencing serious symptoms that were not easily explained away, including deep vein thrombosis in my left leg, extreme weight loss, bruising, wheezing, and shortness of breath so severe that it was difficult to walk my dog more than a few feet without gasping for air. For...
Biomarker-Driven Apalutamide Therapy for Patients With Recurrent Prostate Cancer
Use of PAM50 subtyping allowed clinicians to determine which patients with recurrent prostate cancer were most likely to benefit from the addition of apalutamide hormonal therapy to salvage radiotherapy, according to findings from the phase II BALANCE trial (NRG GU006). These results were presented ...
Medicine Is in the Genes of Neelima Denduluri, MD, FASCO, a Third-Generation Clinician
Growing up in Draksharamam, a small village in India, Neelima Denduluri, MD, FASCO, was attracted to the field of medicine after witnessing her grandfather, a general practitioner in the village, care for patients so poor he often provided medical services at no cost. Although Dr. Denduluri’s...
How a $2 Billion Gift to the Knight Cancer Institute May Accelerate Cancer Advances and Streamline Care for Patients
On August 14, 2025, Oregon Health & Science University (OHSU) announced that Phil Knight, a cofounder of Nike, and his wife, Penny, donated $2 billion to the OHSU Knight Cancer Institute. The record-setting gift is the largest single donation ever made to a U.S. university, college, or academic ...
Postsurgical ctDNA Testing in Stage III Colon Cancer for Treatment De-escalation
Circulating tumor DNA (ctDNA) was found to be a strong prognostic classifier for patients with stage III colon cancer following surgery, according to findings from the phase II/III DYNAMIC-III trial. Findings from the study presented at the European Society for Medical Oncology (ESMO) Congress 2025 ...
How Embedding an Algorithm-Based Referral System Into Electronic Health Records Is Increasing Access to Palliative Care
Despite numerous studies showing the benefits of integrating palliative care in both the early- and advanced-stage cancer settings,1 palliative care remains underutilized for most patients with cancer. A recent study by the American Cancer Society found that only 10% of Medicare beneficiaries with...
Significant Overall Survival Benefit With Enzalutamide Plus Leuprolide for Biochemically Recurrent Prostate Cancer
Enzalutamide in combination with leuprolide demonstrated a significantly longer overall survival than either leuprolide or enzalutamide monotherapy in patients with biochemically recurrent prostate cancer, according to the final overall survival analysis of the phase III EMBARK trial presented at...
Patients Value Communication Skills From Cancer Surgeons Across Six Key Areas
When seeking a surgeon for treatment, providing emotional support and helping patients manage expectations are among the top areas of communication valued by patients, according to a recent systematic review. The research was presented at the 2025 American College of Surgeons (ACS) Clinical...
Considerations on Cancer Drug Development
In the 1940s, the first drugs proven to cause objective responses in human cancers were developed. Mechlorethamine was discovered as a possible treatment of lymphoid cancers after autopsies on military personnel exposed to mustard gas found destruction of lymphatic tissue and bone marrow....
Pulsed Low-Dose–Rate Chemoradiation Reduces Severe Esophagitis in Esophageal Cancer and NSCLC
Chemoradiation with a pulsed low-dose–rate technique led to lower-than-usual rates of severe esophagitis without compromising efficacy in patients with esophageal and non–small cell lung cancer (NSCLC), according to findings from a single-arm phase I study presented as a poster during the American...
Network of Cancer Drug Repositories Improves Access to Treatment, Reduces Waste
A new study found that implementing a network of cancer drug repositories (CDRs) improved access to cancer medications and eliminated unnecessary medication waste by allowing people to donate unopened or unused medications that would otherwise be wasted. This resulted in patients with cancer...
Impact of Proton and Photon Therapies on HRQOL in Breast Cancer
Health-related quality-of-life measurements demonstrated that both proton and photon radiation therapies led to excellent and similar impacts on quality of life for patients with breast cancer undergoing comprehensive nodal irradiation, according to findings from the phase III RadComp trial that...
Oropharyngeal Cancer Quality-of-Life Outcomes: IMRT vs Proton-Beam Therapy
A new phase III clinical trial has found that intensity-modulated radiation therapy (IMRT) and proton-beam therapy resulted in similar quality-of-life outcomes and low rates of side effects for people with locally advanced oropharyngeal cancer. The TORPEdO trial, a randomized study conducted across ...
Adjuvant Radiation Therapy Safe and Beneficial in Locally Advanced Muscle-Invasive Bladder Cancer
Adjuvant radiation therapy following radical cystectomy and chemotherapy was found to be safe and efficacious for patients with locally advanced muscle-invasive bladder cancer, according to findings from the phase III randomized BART trial presented at the American Society for Radiation Oncology...
PAM50 Subtyping Identifies Patients With Prostate Cancer Most Likely to Benefit From Apalutamide
Assessment with a genomic test could help predict which patients with recurrent prostate cancer are most likely to benefit from the addition of hormonal therapy to radiation following prostatectomy, according to findings from the phase II BALANCE trial (NRG GU006) presented in a press briefing...
Can Nicotinamide Reduce the Risk of Skin Cancer Development?
The dietary supplement nicotinamide has been recommended by dermatologists for people with a history of skin cancer since 2015, when a clinical study published by Chen et al in The New England Journal of Medicine including almost 400 participants showed that those who took the vitamin B3 derivative ...
Perioperative Use of Nivolumab With or Without Ipilimumab for Resectable Diffuse Pleural Mesothelioma
Perioperative use of nivolumab with or without ipilimumab may prove to be of benefit for patients with resectable diffuse pleural mesothelioma, according to the findings of a phase II study published in Nature Medicine. Findings from the study were also presented during the International...
Overall Survival Benefit Shown for Neoadjuvant Nivolumab Plus Chemotherapy in Non–Small Cell Lung Cancer
In the preplanned final analysis of the phase III CheckMate 816 trial, an overall survival benefit has been shown for neoadjuvant nivolumab plus chemotherapy in patients with resectable non–small cell lung cancer (NSCLC).1 Patients treated with the combination experienced an approximate 10%...
ASCO Approves First Guideline on Cancer-Specific Geriatric Assessment of Older Patients in Resource-Limited Settings
On April 22, 2025, an ASCO Expert Panel voted to approve ASCO’s global guideline on geriatric assessment of patients with cancer older than age 65 who are being treated in resource-limited settings or countries.1 Guideline recommendations were informed by the ADAPTE methodology and formal consensus ...
How a Novel Coaching Intervention Is Building Resilience and Hope in Adolescents and Young Adults With Advanced Cancer
Each year, nearly 90,000 adolescents and young adults (AYAs; aged 15–39) are diagnosed with cancer, and approximately 9,300 die of the disease.1 And although the 5-year survival rate among these young patients is approaching 80%, it lags behind that of the pediatric population, whose 5-year...
Bridging the Gap in Geriatric Oncology Education: A Global Imperative
As the global population ages, oncology faces an urgent challenge: ensuring that health-care professionals are adequately trained to address the unique complexities of cancer care for older adults. Despite the increasing prevalence of cancer in this demographic, geriatric oncology education remains ...
Is Cure Finally Achievable in Multiple Myeloma?
After decades of incremental progress in the treatment of multiple myeloma, survival has increased from 3 years in the late 1990s to between 8 and 10 years today.1 Could cure for a disease that kills more than 12,000 individuals each year in the United States2 finally be within reach? The long-term ...
Living With the Real-World Consequences of Federal Budget Cuts on Cancer Research
The outlook for adequate funding for federal health agencies has become more dire. In July, the National Cancer Institute (NCI) announced it is reducing the number of grant applications it will award for the remaining 2 months of fiscal year 2025 (FY2025), from 9% down to 4%.1 The result is that...
A Year of Global Progress Against Cancer—and Persistent Challenges
Despite data from the latest edition of The Cancer Atlas showing that nearly half of cancer mortality worldwide is attributed to modifiable risk factors, cancer incidence and mortality rates continue to soar.1 Globally, approximately 19 million new cases of cancer, excluding nonmelanoma skin...
Lifileucel Demonstrates Feasibility and Disease Stability in Advanced Head and Neck Squamous Cell Carcinoma
A single administration of autologous tumor-infiltrating lymphocyte cell therapy with lifileucel led to disease stability in patients with recurrent and/or metastatic head and neck squamous cell carcinoma, even among patients whose disease had progressed or did not respond to multiple prior...
How the AI-Powered ASCO® Guidelines Assistant Is Improving Clinical Decision-Making
This past May, ASCO announced its collaboration with Google Cloud to launch the ASCO® Guidelines Assistant, a new interactive tool that allows clinicians to quickly access ASCO’s evidence-based clinical guidelines to facilitate critical clinical decision-making. Developed with Google Cloud’s Vertex ...
Understanding Accelerated Aging in Survivors of Childhood Cancers
Each year in the United States, nearly 16,000 children and adolescents between the ages of birth and 19 are diagnosed with cancer.1 And although survival rates have greatly improved for many types of childhood cancers, with more than 8 in 10 children and adolescents surviving at least 5 years after ...
Gastrointestinal Tumor Microbes May Predict Prognosis and Therapeutic Response
Microbes inside cancerous tumors can influence the spread of disease and the effectiveness of treatment, and those roles make them appealing targets for new therapies. Tumor microbiota–based tools could also help identify high-risk patients and those most susceptible to metastases, and possibly be...
What We Wish We Knew During Fellowship
July marks a significant transition for many professionals, particularly those beginning structured training programs on July 1. This article is designed to support new and current hematology-oncology fellows and trainees in making the most of their training experience. Although not all suggestions ...
BWEL Weight-Loss Trial Reports Success for Patients With Breast Cancer at 1-Year Mark
Patients with stage II or III breast cancer who participated in a remote weight-loss intervention program lost an average of 4.7% of their baseline body weight after 1 year, whereas those in the education-only control group gained an average 1% of their baseline weight, according to a recent report ...
Can Beta Blockers Help Halt the Progression of Triple-Negative Breast Cancer?
Researchers have identified a molecular biomarker in triple-negative breast cancers that may inform when beta blockers can play a role in “switching off” tumor progression. These findings were published by Lam et al in Science Signaling. When stress hormones are released by the body’s nervous...
Cancer-Induced Nerve Injury Identified as Driver of PD-1 Resistance Across Tumor Types
Researchers have uncovered that cancer cells degrade protective nerve coverings, causing cancer-induced nerve injury that can lead to chronic inflammation and resistance to anti–PD-1 immunotherapy, according to findings published in Nature. In exploring the role of perineural invasion and...
Hybrid AI Approach With Uncertainty Quantification for Mammography Reading Supports Safe Workload Reduction
Investigators have developed and tested a hybrid reading strategy for screening mammography images with artificial intelligence (AI) that includes reads from radiologists and a stand-alone AI interpretation of mammograms with an uncertainty quantification. According to study findings published in...
Underlying Mechanisms of Chemoresistance in AML
Researchers have discovered that an isoform of the transcription factor RUNX1 orchestrates chemoresistance in patients with acute myeloid leukemia (AML), according to findings published in Blood Cancer Discovery. They identified that the long-isoform RUNX1C's connection to BTG2 may enable cellular...
OHSU Knight Cancer Institute Receives $2 Billion Commitment From Phil and Penny Knight
Phil Knight, co-founder of Nike, and Penny Knight announced today a record-breaking $2 billion gift to the Oregon Health & Science University’s (OHSU) Knight Cancer Institute to transform the future of cancer care and set a new standard globally. It is the largest single donation ever made to a ...
New Drug-Releasing System Eliminates Bladder Cancer in Over 80% of Patients in a Phase II Trial
A new drug-releasing system, TAR-200, eliminated tumors in 82% of patients in the phase II SunRISe-1 trial (ClinicalTrials.gov identifier NCT04640623) for individuals with high-risk non–muscle-invasive bladder cancer whose disease had previously resisted treatment. In the majority of cases, the...
Real-World Study Highlights Gaps in Hypomethylating Agent Treatment for MDS
Researchers have identified age-, sex-, and race-related disparities around treatment with hypomethylating agents for patients with myelodysplastic syndromes in the United States. The receipt of hypomethylating agents was found to favor younger, male, White patients, according to findings published ...
RCC: Genetic Testing Key to Avoiding Misdiagnosis of Rare Subtypes
Genetic testing may be the only way to differentiate between common and more rare subtypes of renal cell carcinoma (RCC) to prevent misdiagnoses, according to the results of a study published in Human Pathology. Mucinous tubular and spindle cell carcinoma (MTSCC) was found to share many...
Two ACS Studies Show Colorectal Cancer Screening and Early Diagnosis Have Soared in Adults Aged 45 to 49 Years
It has been widely reported that colorectal cancer incidence has been increasing among younger adults under age 50 since the mid-1990s, with a consistent annual increase of 2% among adults aged 20 to 39. This increase prompted the American Cancer Society (ACS), in 2018, and the United States...
Immune Checkpoint Inhibitors, Cardiovascular Health, and a Potentially Protective Biomarker
New research out of Spain has shown that patients with cancer who had lower levels of the biomarker CD69 (receptor on T cells) before starting treatment with immune checkpoint inhibitors (ICIs) had a more negative immune response and were at higher risk of cardiovascular damage and myocarditis.1...
Updated CHEST Guidelines Emphasize Minimally Invasive Surgery for Early-Stage NSCLC
Updated clinical guidelines for the management of patients with early-stage non–small cell lung cancer (NSCLC) from the American College of Chest Physicians (CHEST) recommend use of more minimally invasive procedures and methods where possible. The guidelines, published in the journal CHEST,...
